Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Nomura Lifts CSPC PHARMA (01093.HK) TP to $12.04, Keeps Buy Rating
Recommend 2 Positive 6 Negative 2 |
||||
|
||||
|
Nomura issued a research report expecting that CSPC PHARMA (01093.HK)'s 4Q25 revenue will grow by 20% YoY to RMB7.6 billion, slightly higher than the market consensus of RMB7.4 billion. The broker also anticipated that the sales of finished drugs will ebb by 1% YoY to RMB5 billion, while collaboration revenue will be RMB1.1 billion. Furthermore, Nomura estimated the Group's gross profit margin to hike by 0.3 ppts YoY to 68.5%, with an operating profit margin of 19% and a net profit of RMB1.3 billion. Considering the increase in CSPC PHARMA's collaboration revenue and the corresponding higher profit margin, the broker raised its FY2025/ 2026 revenue forecasts for the Company by 1%/ 7.2%, and elevated its earnings forecasts by 5.9%/ 26.4%. Therefore, the broker kept rating at Buy for the Company, and lifted its target price from $9.11 to $12.04. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
